Notice of NIDA's Participation in PAR-16-330 "Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01)"

Notice Number: NOT-DA-17-047

Key Dates
Release Date:  July 17, 2017

Related Announcements
PAR-16-330

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) will participate, effective immediately, in the Funding Opportunity Announcement (FOA) PAR-16-330 "Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01)".

The following sections of PAR-16-330 have been updated to reflect the participation of NIDA in this Funding Opportunity Announcement (FOA).

Part 1. Overview Information
Components of Participating Organizations
National Institute of Neurological Disorders and Stroke (NINDS)
National Eye Institute (NEI)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Environmental Health Sciences (NIEHS)
National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s) 
93.853; 93.867; 93.846; 93.113; 93.279

Part 2. Section VII. Agency Contacts
The following contacts have been added:

Scientific/Research Contact(s)

Kristopher Bough, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-9800
Email: Boughk@nih.gov

Financial/Grants Management Contact(s)

Amy Connolly
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-4457
Email: connolla@mail.nih.gov

All other aspects of this FOA remain the same

Inquiries

Please direct all inquiries to:

Kristopher Bough, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-9800
Email: Boughk@nih.gov